Clinical results with EGFR inhibitors in NSCLC and their use in the treatment of metastatic disease

2012 ◽  
pp. 34-43
Author(s):  
Cesare Gridelli ◽  
Antonio Rossi
Keyword(s):  
Metastatic Disease ◽  
Clinical Results ◽  
Egfr Inhibitors

Clinical results with EGFR inhibitors in colorectal cancer

2012 ◽  
pp. 44-59
Author(s):  
Erika Martinelli ◽  
Teresa Troiani ◽  
Floriana Morgillo ◽  
Fortunato Ciardiello
Keyword(s):  
Colorectal Cancer ◽  
Clinical Results ◽  
Egfr Inhibitors

EGFR Inhibitors: Clinical Results

2002 ◽  
Vol 1 (6_suppl1) ◽  
pp. S5-S6 ◽  
Author(s):  
Filippo De Marinis ◽  
Fabrizio Nelli ◽  
Giuliana D'Auria
Keyword(s):  
Clinical Results ◽  
Egfr Inhibitors

Synovial Sarcoma of the Anterior Tibialis Tendon

2012 ◽  
Vol 102 (2) ◽  
pp. 157-160
Author(s):  
Nicola Papapietro ◽  
Umile Giuseppe Longo ◽  
Alessio Palumbo ◽  
Antonella Bianchi ◽  
Nicola Maffuli ◽  
...  
Keyword(s):  
Synovial Sarcoma ◽  
Clinical Features ◽  
Metastatic Disease ◽  
Clinical Results ◽  
Radiographic Findings ◽  
Post Traumatic ◽  
Anterior Tibialis

We report the clinical features, radiographic findings, management and results of a patient with a post-traumatic synovial sarcoma of the anterior tibialis tendon. Our patient was managed operatively and with radiotherapy with good clinical results. No evidence of recurrence or metastatic disease was seen at 3-year follow-up. (J Am Podiatr Med Assoc 102(2): 157–160, 2012)

scholarly journals Long-Term Clinical Results and Management following Vitrectomy in Undetected Retinoblastoma Eyes

2020 ◽  
Vol 6 (4) ◽  
pp. 244-250
Author(s):  
Eva Biewald ◽  
Sabrina Schlüter ◽  
Nikolaos E. Bechrakis ◽  
Tobias Kiefer ◽  
Philipp Rating ◽  
...  
Keyword(s):  
Metastatic Disease ◽  
Case Series ◽  
Clinical Results ◽  
University Hospital ◽  
Age At Surgery ◽  
Coats Disease ◽  
Pars Plana ◽  
Preoperative Magnetic Resonance

Introduction: Given the rarity of retinoblastoma and the consequences of accidental vitrectomy in the event of misdiagnosis, reporting on clinical experience in this area is important. Objective: The aim of this study was to analyse the management and complications with a focus on local orbital recurrence and metastatic disease in 10 children vitrectomized in an undetected retinoblastoma eye. Methods: This is a retrospective descriptive case series conducted in a single-centre referral university hospital. Results: From October 1991 to June 2019, 10 patients with a vitrectomy in an unsuspected retinoblastoma eye were included in this study. The main preoperative diagnoses were unilateral inflammation with a suspected lymphoma, uveitis or toxocariasis in 5 cases, vitreous haemorrhage after trauma in 2 cases, and the last 3 were misdiagnosed with Coats disease, rhegmatogenous retinal detachment and congenital cataract. Mean age at surgery was 3 years, ranging from 14 months to 6 and a half years. Nine patients were suffering from unilateral retinoblastoma; these were enucleated and treated with 4–6 cycles of chemotherapy and/or radiation therapy. The sclerotomy sites were infiltrated with tumour cells in 3 cases. In 1 patient, the differential diagnosis of a malignant medulloepithelioma could not be excluded. One patient had bone marrow infiltration on initial presentation; all other patients are healthy without any signs of orbital recurrence or metastatic disease with a mean follow-up of 5.4 years. Conclusion: In children, intraocular tumours, including retinoblastoma and medulloepithelioma, should be ruled out before pars plana vitrectomy is performed. If no doubtless preoperative diagnosis can be established, preoperative magnetic resonance imaging is mandatory. If a vitrectomy in a retinoblastoma eye has been performed, immediate enucleation of the eye with subsequent chemotherapy and orbital radiation is effective to avoid local recurrence and systemic metastases.

scholarly journals Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Chiara Fiorentini ◽  
Salvatore Grisanti ◽  
Deborah Cosentini ◽  
Andrea Abate ◽  
Elisa Rossini ◽  
...  
Keyword(s):  
T Cell ◽  
Metastatic Disease ◽  
Adrenocortical Carcinoma ◽  
Protein Function ◽  
Molecular Mechanisms ◽  
P53 Protein ◽  
Tp53 Gene ◽  
Clinical Results ◽  
Genetic Alterations ◽  
Molecular Alterations

Adrenocortical carcinoma (ACC) is a rare, highly aggressive cancer, often insensitive to conventional chemotherapeutics agents. Early diagnosis, followed by radical surgical resection plus/minus adjuvant mitotane therapy, is nowadays the only valuable option. Unfortunately, one out of four patients has metastatic disease at diagnosis and most of radically resected ACC patients are destined to recur with local or metastatic disease. Numerous efforts aimed at identifying molecular alterations crucial for ACC pathogenesis have been extensively conducted, with the hope to develop new treatments. Indeed, multiple genes and pathways have been identified as potentially targetable in ACC patients; however, despite the strong preclinical rationale, translational findings to clinical trials led to date to disappointing results. The immunotherapeutic intervention targeting T-cell checkpoint molecules has been proposed as well, but results obtained in early studies indicate that ACC patients would be unlikely to benefit from immunotherapy. Genetic alterations of different pathways involved in ACC carcinogenesis are also known substrates of resistance to immunotherapy. Among them, β-catenin gene CTNNB1 and TP53 gene are frequently mutated in ACC samples. Overactivation of the β-catenin pathway and loss of p53 protein function are potential tumor-intrinsic factors that, impacting on the ability of ACC cells to recruit dendritic cells, leading to T-cell exclusion, put this tumor among those that are potentially resistant to immunotherapy. Moreover, the steroid phenotype, which implies glucocorticoids hypersecretion in a subset of ACC, contributes to generating an immunosuppressive microenvironment. Here, we review clinical results of immunotherapy in ACC and we highlight molecular mechanisms driving immunotherapy failure in ACC, suggesting possible approaches to overcome resistance.

Q&A: Apportionment of Musculoskeletal Impairment to Preexisting Metastatic Disease

2017 ◽  
Vol 22 (4) ◽  
pp. 14-15
Author(s):  
Christopher R. Brigham ◽  
James B. Talmage
Keyword(s):  
Metastatic Disease

Correlation of Insulin Test Studies and Clinical Results in a Series of Peptic Ulcer Cases Treated by Vagotomy

1950 ◽  
Vol 14 (2) ◽  
pp. 214-227 ◽  
Author(s):  
Vernon A. Weinstein ◽  
Franklin Hollander ◽  
Frances U. Lauber ◽  
Ralph Colp
Keyword(s):  
Peptic Ulcer ◽  
Clinical Results ◽  
Insulin Test
Sign in / Sign up

Export Citation Format

Share Document